Factor concentrates

Lifeblood works closely with Haemophilia Treatment Centres (HTC) to support the management of patients with bleeding disorders due to deficiencies in coagulation factors. Hospitals may request the following coagulation factors:

Biostate®

Biostate® is a lyophilised concentrate of human coagulation factor VIII and von Willebrand factor (vWF).

Biostate® is used for the management of patients with von Willebrand Disease and occasionally patients with haemophilia A. 

Biostate® is available in three presentations: 

• 250 IU factor VIII 
• 500 IU factor VIII 
• 1000 IU factor VIII 

Biostate® product information

This link takes you to CSL Behring's web information about Biostate®. You can download the product information (PI) sheet from this web page.

The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy and lactation, adverse effects, dosage and administration of Biostate®.

MonoFIX-VF®

MonoFIX-VF® is a lyophilised concentrate of human coagulation factor IX and can be used in the management of patients with haemophilia B (congenital factor IX deficiency or Christmas disease).

MonoFIX-VF® is not indicated for the treatment of factor II, VII or X deficiencies because it does not contain therapeutic levels of these factors, or for the treatment of haemophilia A patients with factor VIII inhibitors. 

MonoFIX-VF® is available in three presentations:

• 500 IU (50 IU/ml) 
• 500 IU (100 IU/mL) 
• 1000 IU (100 IU/mL) 

MonoFIX-VF® product information

This link takes you to CSL Behring's web information about MonoFIX-VF®. You can download the product information (PI) sheet from this web page.

The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy and lactation, adverse effects, dosage and administration of MonoFIX-VF®.

Prothrombinex-VF®

Prothrombinex-VF® is a lyophilised concentrate of human coagulation factors containing factors II, IX and X and a small amount of factor VII.

Prothrombinex-VF® is used management of patients with single or multiple congenital deficiencies of factor II or X, and in patients with single or multiple acquired factor II, IX and X deficiencies caused by vitamin K antagonists (warfarin) requiring partial or complete reversal.

For warfarin reversal, the Prothrombinex-VF® dose is 15–50 IU/kg depending on bleeding risk and initial INR.

Prothrombinex-VF® is available in single vials containing 500 IU of factor II, 500 IU of factor IX and 500 IU of factor X.

Prothrombinex-VF® product information

This link takes you to CSL Behring's web information about Prothrombinex-VF®. You can download the product information (PI) sheet from this web page.

Prothrombinex-VF® consumer information

The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy and lactation, adverse effects, dosage and administration of Prothrombinex-VF®.

Thrombotrol-VF®

Thrombotrol-VF® is a lyophilised concentrate of human antithrombin (also known as antithrombin III or ATIII). It’s used in the treatment of patients with inherited deficiency of antithrombin to provide prophylaxis and treatment of thrombosis during surgery, pregnancy and childbirth.

It may also be indicated in cases of acquired antithrombin deficiencies such as liver disease, following certain chemotherapy (asparaginase) and acute disseminated intravascular coagulation (DIC).

Thrombotrol-VF® is available in single vials nominally containing 1000 IU of antithrombin.

Thrombotrol-VF® product information

This link takes you to CSL Behring's web information about Thrombotrol-VF®. You can download the product information (PI) sheet from this web page.

The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy and lactation, adverse effects, dosage and administration of Thrombotrol-VF®.

Beriplex® P/N

Beriplex® P/N is an imported lyophilised prothrombin complex concentrate (PCC) derived from human plasma. Beriplex® P/N contains factors II, VII, IX and X.

Beriplex® P/N is used management of patients with single or multiple congenital deficiencies of factors II or X, and in patients requiring partial or complete reversal of single or multiple acquired factors II, IX and X deficiencies caused by vitamin K antagonists (e.g. warfarin).

Beriplex® P/N is available in single vials containing approximately 500 IU of factors II, VII and X, and 500 IU of factor IX.

Beriplex® P/N product information

This link takes you to CSL Behring's web information about Beriplex® P/N. You can download the product information (PI) and consumer medicine information (CMI) sheets from this web page.
The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy and lactation, adverse effects, dosage, and administration of Beriplex® P/N.

Guidelines for warfarin reversal are provided by the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) and are expected to be published soon. 

More information about the transition to Beriplex® P/N can be found on CSL Behring’s website Healthcare Portal and on the National Blood Authority’s website.

Recombinant factor IX

Recombinant products are available from Lifeblood in NSW.

BeneFIX®

BeneFIX® is a lyophilised concentrate of recombinant factor IX and can be used in the management of patients with haemophilia B (congenital factor IX deficiency or Christmas disease).

BeneFIX is not indicated for the treatment of other factor deficiencies (e.g. factors II, VII and X), the treatment of haemophilia A patients with inhibitors to factor VIII, the reversal of Vitamin K antagonists (warfarin), or for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

BeneFIX® is available in the following presentations:

• 250 IU 
• 500 IU 
• 1000 IU 
• 2000 IU 
• 3000 IU 

BeneFIX® Product Information

Always refer to and read the product information sheets for further information on precautions, dosage and administration prior to giving coagulation factors.